Mutagenic evaluation of tolbutamide and glybenclamide on the bone marrow cells of mice

Kar, Rohan; Mukherjee, B.; Mukherjee, S. K.

doi:10.1016/0378-4274(86)90205-5

Cited by 7 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since compounds possessing antioxidant and anticancer activities are strongly implicated to exhibit the anti-mutagenic potential[1314] and the mutagenic test for GL was found to be negative,[15] we examined in this study the anti-clastogenic effect of GL against the nicotinamide-STZ induced DNA damage using bone marrow micronucleus and sperm abnormalities tests in male Wistar rats.…”

Section: Introductionmentioning

confidence: 99%

“…[12,13] Thus, mutation tests like micronucleus and sperm abnormality test assume importance as they identify the somatic and germinal cells defects induced by the drug/disease. [13] Since compounds possessing antioxidant and anticancer activities are strongly implicated to exhibit the anti-mutagenic potential [13,14] and the mutagenic test for GL was found to be negative, [15] we examined in this study the anti-clastogenic www.journalonweb.com effect of GL against the nicotinamide-STZ induced DNA damage using bone marrow micronucleus and sperm abnormalities tests in male Wistar rats.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Protective role of glibenclamide against nicotinamidestreptozotocin induced nuclear damage in diabetic Wistar rats

Rabbani

Devi

Khanam

2010

Journal of Pharmacology and Pharmacotherapeutics

View full text Add to dashboard Cite

Objective:To evaluate the protective effect of glibenclamide against the experimental diabetes-induced nuclear damage in Wistar rats.Materials and Methods:The anti-mutagenic effect of glibenclamide (0.5, 5 and 50 mg/kg, p.o daily for 4 weeks) was evaluated against the nicotinamide (NA)-streptozotocin (STZ) induced type-2 diabetes mellitus using bone marrow micronucleus and sperm abnormalities tests. The antioxidant status was tested by estimating the serum levels of lipid peroxidation (LPO), catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GPx).Results:The results indicated that glibenclamide at 50 mg/kg decreased the frequency of micronuclei in erythrocytes (P < 0.05) and sperm shape abnormality (P < 0.01) besides enhancing the antioxidant status (P < 0.05) in the diabetic rats. However, glibenclamide treatment did not enhance the polychromatic and normochromatic erythrocytes (P/N) ratio and sperm count in the diabetic condition.Conclusion:The observations indicate that the glibenclamide has anti-mutagenic potential which could be related to the antioxidant effect and might also possess anti-proliferative property.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Protective role of glibenclamide against nicotinamidestreptozotocin induced nuclear damage in diabetic Wistar rats

Rabbani

Devi

Khanam

2010

Journal of Pharmacology and Pharmacotherapeutics

View full text Add to dashboard Cite

show abstract

Chromosome aberration and sister chromatid exchange tests in chinese hamster ovary cells in vitro. V: Results With 46 Chemicals

Ivett¹,

Brown²,

Rodgers³

et al. 1990

Environ and Mol Mutagen

140

View full text Add to dashboard Cite

Forty-six coded chemicals were tested for their ability to induce sister chromatid exchanges (SCEs) and chromosomal aberrations (ABs) in cultured Chinese hamster ovary (CHO) cells using a standard protocol with and without exogenous metabolic activation. Sixteen chemicals were negative and 15 were positive in both assays; 15 were positive for SCEs only (one chemical that was positive for SCEs was equivocal for ABs), and no chemicals induced ABs only. The effect of cell harvest time on the ability to detect the induction of ABs was examined for 18 chemicals. Seven chemicals produced a positive response using both standard and extended harvest times, five were positive only using an extended harvest time, and six were negative using both harvest times. The relationship between cell cycle delay and SCE induction was also examined, and the two appear to be unrelated.

show abstract

Bone marrow micronucleus assay: A review of the mouse stocks used and their published mean spontaneous micronucleus frequencies

Salamone

Mavournin

1994

Environ and Mol Mutagen

View full text Add to dashboard Cite

We have examined published negative control data from 581 papers on micronucleated bone marrow polychromatic erythrocytes (mnPCE) for differences in mean frequency and the frequency distribution profile among the mouse stocks used with the bone marrow micronucleus assay. For the 55 mouse stocks with published micronucleus assay data, the overall mean frequency is 1.95 mnPCE/1,000 PCE (1.95 mnPCE/1,000); for the 13 stocks most commonly used in the assay, it is 1.88 mnPCE/1,000. During the last 5 years, the mnPCE rate for these 13 major stocks has been 1.74 mnPCE/1,000. This current mean frequency is a substantial decrease from the mean of 3.07 mnPCE/1,000 observed for these 13 stocks for data published prior to 1981. Of the major stocks, the highest mean mnPCE negative control frequencies were observed for MS/Ae > BALB/c > C57Bl/6, and the lowest for CD-1 < Swiss Webster. We note that hybrid mouse stocks appear to have lower and less variable negative control frequencies than either of their parent strains and that the negative control frequency for some progeny stocks have diverged significantly from that of the parent stocks. Overall mean negative control frequencies appear to be correlated with breadth of the frequency distribution profile of published mean negative control values. Furthermore, a possible correlation between negative control frequency in the micronucleus assay and sensitivity to clastogens of different mouse strains may be indicated. The databases generated here allow us to define a range of norms for both the historical mean frequency and individual experimental mean frequencies for most stocks, but in particular, for the more commonly used mouse stocks. Our analysis, for the most part, bears out the recommendation of the first Gene-Tox Report on the micronucleus assay that the historical negative control frequency for a mouse stock should fall between 1 and 3 mnPCE/1,000. Eighty-six percent of the most commonly used mouse stocks have historical mean frequencies within this range. Though individual experimental mean values would not necessarily be expected to fall within the 1-3.00 mnPCE/1,000 range, 65.3% of the 2,327 published negative control values do, and 83.5% are < 3 mnPCE/1,000. The frequency with which an individual experimental mean value lies outside the 1.00 to 3.00 mnPCE/1,000 range differs among stocks and appears related to the mouse mean frequency. We suggest that the recommended range for historical mean frequency be extended slightly, to approximately 3.4 mnPCE/1,000, to accommodate some commonly used strains with overall mean negative control frequencies just above 3.00 mnPCE/1,000.(ABSTRACT TRUNCATED AT 400 WORDS)

show abstract

Mutagenic evaluation of tolbutamide and glybenclamide on the bone marrow cells of mice

Cited by 7 publications

References 17 publications

Protective role of glibenclamide against nicotinamidestreptozotocin induced nuclear damage in diabetic Wistar rats

Protective role of glibenclamide against nicotinamidestreptozotocin induced nuclear damage in diabetic Wistar rats

Chromosome aberration and sister chromatid exchange tests in chinese hamster ovary cells in vitro. V: Results With 46 Chemicals

Bone marrow micronucleus assay: A review of the mouse stocks used and their published mean spontaneous micronucleus frequencies

Contact Info

Product

Resources

About